Fuwai hospital
Beijing, Beijing Municipality, China
NCT Number: NCT02883842
The study is a two-arm, parallel, randomized clinical trial. The purpose of the study is to evaluate the effectiveness of automated mobile phone text message-based intervention for secondary prevention, including lifestyles modification, medication adherence improvement and risk factors control among coronary heart disease (CHD) patients with diabetes. The participants will be randomized into intervention and control groups in a 1:1 ratio. The intervention group will receive 6 pre-designed text messages per week in addition to usual care for 6 months, while the control group will receive usual care.
Looking for future studies?
Notify Me18 year–90 year
All sexes
Interventional
Not applicable
Beijing, Beijing Municipality, China
Objective: This study aims to evaluate the effectiveness of automated mobile phone text message-based intervention for secondary prevention, including lifestyles modification, medication adherence improvement and risk factors control among CHD patients with diabetes. We hypothesized that an intervention using mobile phone text based education and reminder can improve risk factors control and medication adherence for CHD patients.
Study design: The study is a two-arm, parallel, randomized clinical trial. Patients will be eligible if they have documented CHD defined as having history of myocardial infarction and percutaneous coronary intervention (PCI), have a history of diabetes mellitus, have the capability of reading and sending short message, and are able to provide informed consent. Patients will be excluded if they do not have an active mobile phone. The eligible participants will be allocated into intervention and control groups in a 1:1 ratio randomly. The intervention group will receive intervention of pre-designed text messages in addition to usual care, while the control group will receive usual care. All the participants will be followed up for 6 months.
Study intervention: Participants in the intervention group will receive text messages for 6 months as well as usual care. They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week.
Outcome measures: The primary endpoint is the change in glycemic hemoglobin (HbA1C) as measured by central blood sample. Secondary endpoints include a change in proportion of patients achieving HbA1C<7%, body mass index (BMI), physical activity, medication adherence, systolic blood pressure, low-density lipoprotein cholesterol (LDL-C) and fasting blood glucose (FBG). Exploratory endpoints include long-term prognosis of the patients, such as death, nonfatal myocardial infarction, stroke and so on, as well as health status (SAQ and EQ-5D).
Statistical analysis: Evaluation will be carried out on an intention-to-treat basis. Values of analyzed endpoints between intervention group and control group will be compared according to the analysis plan. We'll follow a prespecified analysis plan and subgroup analysis will be conducted accordingly.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week. Prior to study commencement, a bank of 270 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
Time frame: Baseline; 6 months
We will measured the change in glucose level from baseline to 6 months.
Time frame: Baseline; 6 months
We will measure the change in proportion of patients achieving HbA1C<7% from baseline to 6 months.
Time frame: Baseline; 6 months
We will measure the change in FBG level from baseline to 6 months.
Time frame: Baseline; 6 months
We will measured the change in BMI from baseline to 6 months.
Time frame: Baseline; 6 months
We will measured the change in SBP from baseline to 6 months.
Time frame: Baseline; 6 months
We will measure the change in IPAQ scale from baseline to 6 months.
Time frame: Baseline; 6 months
We will measure the change in medication adherence from baseline to 6 months.
Time frame: Baseline; 6 months
We will measure the change in LDL-C level from baseline to 6 months.
China National Center for Cardiovascular Diseases
Other Gov
Effectiveness of Text Messaging on Risk Factors Control and Medication Adherence Among Patients With Coronary Heart Disease and Diabetes in China: Cardiovascular Health and Text Messaging-Diabetes Mellitus (CHAT-DM) Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03360981
Arterial Occlusive Diseases, Arteriosclerosis
Naples, Italy
View Trial DetailsNCT00628524
Arterial Occlusive Diseases, Arteriosclerosis
Homburg, Saarland, Germany
View Trial DetailsNCT04234334
Arterial Occlusive Diseases, Arteriosclerosis
Storrs, Connecticut, United States
View Trial DetailsNCT05208424
Arterial Occlusive Diseases, Arteriosclerosis
Dammam, Saudi Arabia
View Trial Details